{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["27(11)"],"submitter":["Alves Pinto I"],"funding":["AstraZeneca do Brasil Ltda"],"pubmed_abstract":["<h4>Background</h4>Targeted and immunotherapies are currently moving toward early-stage settings for patients with non-small cell lung cancer (NSCLC). Predictive biomarkers data are scarce in this scenario. We aimed to describe the frequency of EGFR mutations and PD-L1 expression levels in early-stage non-squamous patients with NSCLC from a large, single Brazilian oncology center.<h4>Methods</h4>We retrospectively evaluated patients with NSCLC diagnosed at an early-stage (IB to IIIA-AJCC seventh edition) at Barretos Cancer Hospital (n = 302). EGFR mutational status was assessed in FFPE tumor tissues using distinct methodologies (NGS, Cobas, or Sanger sequencing). PD-L1 expression was evaluated by immunohistochemistry (clone 22C3) and reported as Tumor Proportion Score (TPS), categorized as"],"journal":["The oncologist"],"pagination":["e899-e907"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9632322"],"repository":["biostudies-literature"],"pubmed_title":["EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil."],"pmcid":["PMC9632322"],"pubmed_authors":["Oliveira da Silva M","Biazotto Fernandes MF","Berardinelli GN","Jacinto AA","Junqueira Pinto GD","de Oliveira Cavagna R","Virginio da Silva AL","Negreiros IS","Duval da Silva V","Reis RM","Albino da Silva EC","Dias JM","Santiago Goncalves MF","Leal LF","de Oliveira MA","Alves Pinto I","Ferreira da Silva FA","Souza LC","de Paula FE","Casagrande GMS","Santana IV","De Marchi P"],"additional_accession":[]},"is_claimable":false,"name":"EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil.","description":"<h4>Background</h4>Targeted and immunotherapies are currently moving toward early-stage settings for patients with non-small cell lung cancer (NSCLC). Predictive biomarkers data are scarce in this scenario. We aimed to describe the frequency of EGFR mutations and PD-L1 expression levels in early-stage non-squamous patients with NSCLC from a large, single Brazilian oncology center.<h4>Methods</h4>We retrospectively evaluated patients with NSCLC diagnosed at an early-stage (IB to IIIA-AJCC seventh edition) at Barretos Cancer Hospital (n = 302). EGFR mutational status was assessed in FFPE tumor tissues using distinct methodologies (NGS, Cobas, or Sanger sequencing). PD-L1 expression was evaluated by immunohistochemistry (clone 22C3) and reported as Tumor Proportion Score (TPS), categorized as","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2026-07-14T16:04:14.094Z","creation":"2024-11-08T20:16:10.234Z"},"accession":"S-EPMC9632322","cross_references":{"pubmed":["36099421"],"doi":["10.1093/oncolo/oyac167"]}}